198 related articles for article (PubMed ID: 21046532)
1. [Biologicals in gastroenterology: TNF-blockers].
Scharl M; Rogler G
Dtsch Med Wochenschr; 2010 Nov; 135(45):2243-52. PubMed ID: 21046532
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
3. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
4. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
Hellström PM; Schmidt D; Karlén P
Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
[No Abstract] [Full Text] [Related]
5. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
6. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
7. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
9. [Biologicals first-line in chronic inflammatory bowel disease? No].
Herrlinger K; Stange EF
Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
[No Abstract] [Full Text] [Related]
10. The use of biologic agents in pediatric inflammatory bowel disease.
Yang LS; Alex G; Catto-Smith AG
Curr Opin Pediatr; 2012 Oct; 24(5):609-14. PubMed ID: 22828183
[TBL] [Abstract][Full Text] [Related]
11. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry RB; Irving PM
J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
[No Abstract] [Full Text] [Related]
12. [Inflammatory bowel diseases--new therapeutic options].
Herrlinger K; Stange EF
Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
[No Abstract] [Full Text] [Related]
13. The safety of biologic agents in the treatment of inflammatory bowel disease.
Shepela C
Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic approach in inflammatory bowel disease.
Papa A; Mocci G; Scaldaferri F; Bonizzi M; Felice C; Andrisani G; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():33-5. PubMed ID: 19530509
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
16. [Drug therapy of inflammatory bowel diseases].
Silvennoinen J; Niemelä S
Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
[No Abstract] [Full Text] [Related]
17. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
[TBL] [Abstract][Full Text] [Related]
19. [Introduction to biological drugs].
Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
[TBL] [Abstract][Full Text] [Related]
20. [Inflammatory bowel disease: anti-TNF strategies and beyond].
Hoffmann JC
Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S76-8. PubMed ID: 15368175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
